 |
|  |
Jan-08-21 | Downgrade |
Wells Fargo |
Overweight → Equal Weight |
$110 |
|
Sep-14-20 | Resumed |
JP Morgan |
Neutral |
$103 |
|
Jul-31-20 | Reiterated |
Chardan Capital Markets |
Buy |
$86 → $112 |
|
Sep-12-19 | Initiated |
Guggenheim |
Buy |
|
|
Sep-04-19 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
Nov-02-18 | Upgrade |
Goldman |
Neutral → Buy |
|
|
Aug-03-18 | Reiterated |
Chardan Capital Markets |
Buy |
$53 → $57 |
|
Jun-13-18 | Initiated |
Argus |
Buy |
$62 |
|
Apr-25-18 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
Jan-24-18 | Initiated |
Goldman |
Neutral |
|
|
Jan-16-18 | Reiterated |
Chardan Capital Markets |
Buy |
$47 → $53 |
|
Jun-28-16 | Reiterated |
Singular Research |
Buy |
$44 → $40 |
|
Apr-15-16 | Initiated |
Chardan Capital Markets |
Buy |
$47 |
|
Mar-28-16 | Initiated |
Singular Research |
Buy |
$44 |
|
Feb-19-16 | Initiated |
Wells Fargo |
Outperform |
|
|
May-15-14 | Initiated |
Summer Street Research |
Buy |
$35 |
|
May-31-11 | Reiterated |
WBB Securities |
Strong Buy |
$20.50 → $30 |
|
Jan-10-11 | Reiterated |
Wedbush |
Outperform |
$27 → $32 |
|
Nov-05-10 | Reiterated |
Wedbush |
Outperform |
$22 → $27 |
|
Aug-18-10 | Upgrade |
WBB Securities |
Buy → Strong Buy |
$20.50 |
|
|
 |
Jan-13-21 01:38PM | Investor's Business Daily |
Jan-12-21 10:37AM | |
Jan-11-21 09:22AM | |
09:15AM | |
Jan-10-21 02:00PM | |
Jan-07-21 12:45PM | |
Jan-06-21 05:50PM | |
11:30AM | |
Jan-05-21 07:03AM | |
Jan-04-21 03:25PM | |
06:30AM | |
Dec-31-20 09:40AM | |
Dec-30-20 11:21AM | |
Dec-29-20 04:05PM | |
Dec-18-20 08:15PM | |
Dec-17-20 09:19AM | |
Dec-16-20 11:56PM | |
Dec-15-20 09:38AM | |
Dec-05-20 11:32AM | |
Dec-02-20 12:35PM | |
Nov-27-20 06:14AM | |
Nov-18-20 09:30AM | |
Nov-10-20 09:40AM | |
Nov-09-20 10:18AM | |
08:58AM | |
Nov-06-20 06:50PM | |
11:16AM | |
10:57AM | |
10:54AM | |
10:52AM | |
10:51AM | |
10:43AM | |
08:00AM | Investor's Business Daily |
Nov-05-20 07:40PM | |
04:05PM | |
03:15PM | |
11:38AM | |
08:58AM | |
Nov-04-20 09:52AM | |
Nov-03-20 10:29AM | |
10:26AM | |
10:14AM | |
09:36AM | |
Nov-02-20 12:46PM | |
11:06AM | |
Oct-30-20 03:54PM | |
Oct-29-20 05:45PM | |
02:25PM | Investor's Business Daily |
12:34PM | |
11:24AM | |
Oct-28-20 10:32AM | |
Oct-23-20 05:45PM | |
Oct-21-20 11:30AM | |
10:48AM | |
Oct-20-20 10:26AM | |
Oct-19-20 10:09AM | |
10:05AM | |
09:55AM | |
Oct-16-20 09:58AM | |
08:54AM | |
Oct-15-20 05:45PM | |
12:45PM | |
10:24AM | |
Oct-14-20 10:03AM | |
Oct-13-20 12:31PM | |
10:36AM | Investor's Business Daily |
10:32AM | |
10:30AM | |
09:47AM | |
09:45AM | |
08:30AM | |
Oct-12-20 09:45AM | |
08:50AM | |
Oct-09-20 08:40AM | |
08:32AM | |
Oct-08-20 04:05PM | |
11:37AM | |
08:37AM | |
Oct-07-20 10:49AM | |
10:46AM | |
Oct-06-20 09:19AM | |
Oct-05-20 12:46PM | |
11:30AM | |
Sep-21-20 04:25AM | |
Sep-18-20 11:30AM | |
Sep-16-20 12:19PM | Investor's Business Daily |
Sep-15-20 10:48AM | Investor's Business Daily |
Sep-11-20 05:50PM | |
Sep-10-20 12:11PM | Investor's Business Daily |
Sep-08-20 04:34AM | Investor's Business Daily |
Sep-04-20 11:41AM | Investor's Business Daily |
Sep-02-20 11:30AM | |
09:55AM | |
Sep-01-20 10:10AM | |
Aug-31-20 06:30AM | |
Aug-29-20 11:31AM | |
Aug-26-20 01:33PM | Investor's Business Daily |
01:11PM | Investor's Business Daily |
12:23PM | Investor's Business Daily |
08:04AM | |
|
|
|
 |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland. |
 |
|  |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
El-Hibri Fuad | Chairman | Nov 10 | Option Exercise | 26.45 | 19,391 | 512,892 | 1,143,379 | Nov 12 06:30 PM | El-Hibri Fuad | Chairman | Nov 10 | Sale | 88.21 | 19,391 | 1,710,480 | 1,123,988 | Nov 12 06:30 PM | El-Hibri Fuad | Chairman | Nov 09 | Option Exercise | 26.45 | 20,000 | 529,000 | 1,143,988 | Nov 12 06:30 PM | El-Hibri Fuad | Chairman | Nov 09 | Sale | 95.26 | 20,000 | 1,905,200 | 1,123,988 | Nov 12 06:30 PM | El-Hibri Fuad | Chairman | Nov 03 | Option Exercise | 26.45 | 20,000 | 529,000 | 1,143,988 | Nov 04 08:53 PM | El-Hibri Fuad | Chairman | Nov 03 | Sale | 90.74 | 20,000 | 1,814,800 | 1,123,988 | Nov 04 08:53 PM | El-Hibri Fuad | Chairman | Nov 02 | Option Exercise | 26.45 | 20,000 | 529,000 | 1,143,988 | Nov 04 08:53 PM | El-Hibri Fuad | Chairman | Nov 02 | Sale | 90.44 | 20,000 | 1,808,800 | 1,123,988 | Nov 04 08:53 PM | El-Hibri Fuad | Chairman | Sep 24 | Sale | 98.85 | 12,535 | 1,239,085 | 1,123,988 | Sep 25 07:00 PM | El-Hibri Fuad | Chairman | Sep 23 | Sale | 100.58 | 13,000 | 1,307,540 | 1,136,523 | Sep 25 07:00 PM | El-Hibri Fuad | Chairman | Sep 17 | Sale | 100.68 | 20,000 | 2,013,600 | 1,149,523 | Sep 18 06:25 PM | El-Hibri Fuad | Chairman | Sep 16 | Sale | 102.48 | 20,000 | 2,049,600 | 1,169,523 | Sep 18 06:25 PM | El-Hibri Fuad | Chairman | Sep 10 | Sale | 102.66 | 20,000 | 2,053,200 | 1,189,523 | Sep 11 09:21 PM | El-Hibri Fuad | Chairman | Sep 09 | Sale | 102.80 | 20,000 | 2,056,000 | 1,209,523 | Sep 11 09:21 PM | SULLIVAN LOUIS W | Director | Sep 02 | Option Exercise | 20.08 | 7,893 | 158,491 | 50,655 | Sep 04 08:08 PM | SULLIVAN LOUIS W | Director | Sep 02 | Sale | 111.22 | 28,418 | 3,160,606 | 42,762 | Sep 04 08:08 PM | Bailey Sue | Director | Aug 18 | Sale | 128.31 | 4,665 | 598,564 | 32,595 | Aug 19 05:08 PM | Harsanyi Zsolt | Director | Aug 17 | Sale | 133.71 | 6,609 | 883,664 | 24,579 | Aug 18 09:12 AM | JOULWAN GEORGE A | Director | Aug 11 | Sale | 124.11 | 6,000 | 744,635 | 26,771 | Aug 12 04:52 PM | Zoon Kathryn C | Director | Aug 10 | Sale | 130.27 | 1,000 | 130,270 | 12,489 | Aug 11 04:43 PM | Richard Ronald | Director | Aug 07 | Sale | 131.00 | 6,297 | 824,907 | 8,276 | Aug 11 04:46 PM | Richard Ronald | Director | Jun 03 | Sale | 87.51 | 6,572 | 575,142 | 4,269 | Jun 05 04:36 PM | Bailey Sue | Director | Jun 03 | Sale | 87.50 | 5,322 | 465,691 | 37,260 | Jun 05 04:33 PM | Hauer Jerome M | Director | May 26 | Sale | 85.15 | 4,385 | 373,373 | 10,188 | May 27 05:10 PM | Zoon Kathryn C | Director | May 26 | Sale | 85.10 | 4,093 | 348,322 | 13,489 | May 27 05:07 PM | Harsanyi Zsolt | Director | May 14 | Option Exercise | 18.64 | 3,434 | 64,010 | 28,367 | May 18 07:12 PM | Zoon Kathryn C | Director | May 12 | Sale | 85.21 | 1,660 | 141,454 | 14,761 | May 14 04:30 PM | Harsanyi Zsolt | Director | May 11 | Sale | 81.99 | 4,940 | 405,025 | 24,933 | May 13 07:47 PM | JOULWAN GEORGE A | Director | May 11 | Sale | 85.19 | 2,000 | 170,371 | 29,950 | May 13 07:45 PM | Richard Ronald | Director | May 05 | Sale | 80.19 | 8,375 | 671,629 | 8,020 | May 06 05:08 PM | El-Hibri Fuad | Chairman | Apr 30 | Sale | 74.01 | 20,000 | 1,480,200 | 1,229,523 | May 01 08:13 PM | El-Hibri Fuad | Chairman | Apr 29 | Sale | 74.24 | 20,000 | 1,484,800 | 1,249,523 | May 01 08:13 PM | Richard Ronald | Director | Apr 27 | Option Exercise | 20.08 | 7,893 | 158,491 | 24,288 | Apr 29 04:35 PM | Richard Ronald | Director | Apr 27 | Sale | 78.00 | 7,893 | 615,654 | 16,395 | Apr 29 04:35 PM | El-Hibri Fuad | Chairman | Apr 23 | Sale | 68.49 | 20,000 | 1,369,800 | 1,269,523 | Apr 24 04:16 PM | El-Hibri Fuad | Chairman | Apr 22 | Sale | 66.81 | 20,000 | 1,336,200 | 1,289,523 | Apr 24 04:16 PM | Havey Adam | EVP, Business Operations | Apr 20 | Option Exercise | 30.86 | 17,009 | 524,898 | 51,265 | Apr 21 06:12 PM | Havey Adam | EVP, Business Operations | Apr 20 | Sale | 69.00 | 17,009 | 1,173,621 | 34,256 | Apr 21 06:12 PM | Havey Adam | EVP, Business Operations | Apr 17 | Option Exercise | 26.45 | 20,414 | 539,950 | 54,670 | Apr 21 06:12 PM | Havey Adam | EVP, Business Operations | Apr 17 | Sale | 65.00 | 20,414 | 1,326,910 | 34,256 | Apr 21 06:12 PM | El-Hibri Fuad | Chairman | Apr 16 | Sale | 62.47 | 20,000 | 1,249,400 | 1,309,523 | Apr 20 06:30 PM | El-Hibri Fuad | Chairman | Apr 15 | Sale | 62.58 | 12,537 | 784,565 | 1,329,523 | Apr 15 09:04 PM | El-Hibri Fuad | Chairman | Apr 14 | Sale | 62.99 | 6,261 | 394,380 | 1,342,060 | Apr 15 09:04 PM | El-Hibri Fuad | Chairman | Apr 13 | Sale | 62.25 | 17,071 | 1,062,670 | 1,348,321 | Apr 15 09:04 PM | El-Hibri Fuad | Chairman | Apr 09 | Sale | 61.83 | 23,716 | 1,466,360 | 1,365,392 | Apr 10 07:13 PM | El-Hibri Fuad | Chairman | Apr 08 | Sale | 61.13 | 37,362 | 2,284,115 | 1,389,108 | Apr 10 07:13 PM | El-Hibri Fuad | Chairman | Apr 07 | Sale | 60.76 | 14,336 | 871,055 | 1,426,470 | Apr 08 09:17 PM | Kirk Sean | EVP, Manufacturing & Tech Ops | Apr 06 | Option Exercise | 30.70 | 10,428 | 320,131 | 19,864 | Apr 08 08:19 PM | El-Hibri Fuad | Chairman | Apr 06 | Sale | 60.50 | 28,240 | 1,708,520 | 1,440,806 | Apr 08 09:17 PM | Havey Adam | EVP, Business Operations | Apr 06 | Sale | 60.00 | 7,972 | 478,320 | 34,256 | Apr 08 08:22 PM | Kirk Sean | EVP, Manufacturing & Tech Ops | Apr 06 | Sale | 60.00 | 16,094 | 965,640 | 12,571 | Apr 08 08:19 PM | Harsanyi Zsolt | Director | Mar 16 | Sale | 65.00 | 6,400 | 416,000 | 29,873 | Mar 17 04:39 PM | SULLIVAN LOUIS W | Director | Mar 04 | Option Exercise | 13.86 | 15,786 | 218,715 | 68,359 | Mar 06 04:37 PM | Zoon Kathryn C | Director | Mar 04 | Sale | 60.65 | 991 | 60,103 | 16,421 | Mar 06 04:39 PM | SULLIVAN LOUIS W | Director | Mar 04 | Sale | 58.96 | 15,786 | 930,714 | 60,466 | Mar 06 04:37 PM | Bailey Sue | Director | Feb 27 | Sale | 56.93 | 6,572 | 374,132 | 39,761 | Mar 02 05:28 PM | El-Hibri Fuad | Chairman | Feb 27 | Sale | 56.97 | 9,837 | 560,414 | 1,469,046 | Feb 28 08:01 PM | El-Hibri Fuad | Chairman | Feb 26 | Sale | 58.70 | 13,619 | 799,435 | 1,472,943 | Feb 28 08:01 PM | El-Hibri Fuad | Chairman | Feb 21 | Option Exercise | 25.62 | 18,567 | 475,687 | 1,497,585 | Feb 24 08:00 PM | Richard Ronald | Director | Feb 21 | Option Exercise | 18.64 | 5,152 | 96,033 | 31,851 | Feb 25 04:30 PM | Richard Ronald | Director | Feb 21 | Sale | 65.00 | 5,152 | 334,880 | 16,395 | Feb 25 04:30 PM | Hauer Jerome M | Director | Feb 21 | Sale | 70.00 | 6,572 | 460,040 | 11,752 | Feb 25 04:28 PM | El-Hibri Fuad | Chairman | Feb 21 | Sale | 64.90 | 18,567 | 1,204,998 | 1,479,018 | Feb 24 08:00 PM | El-Hibri Fuad | Chairman | Feb 20 | Option Exercise | 25.62 | 4,751 | 121,721 | 1,483,769 | Feb 24 08:00 PM | El-Hibri Fuad | Chairman | Feb 20 | Sale | 64.90 | 4,751 | 308,340 | 1,479,018 | Feb 24 08:00 PM | El-Hibri Fuad | Chairman | Feb 18 | Option Exercise | 25.62 | 15,614 | 400,031 | 1,494,632 | Feb 19 09:00 PM | El-Hibri Fuad | Chairman | Feb 18 | Sale | 63.90 | 15,614 | 997,735 | 1,479,018 | Feb 19 09:00 PM | El-Hibri Fuad | Chairman | Feb 14 | Option Exercise | 25.62 | 4,386 | 112,369 | 1,483,404 | Feb 19 09:00 PM | El-Hibri Fuad | Chairman | Feb 14 | Sale | 63.90 | 4,386 | 280,265 | 1,479,018 | Feb 19 09:00 PM | El-Hibri Fuad | Chairman | Feb 12 | Option Exercise | 25.62 | 13,720 | 351,506 | 1,492,738 | Feb 13 06:30 PM | El-Hibri Fuad | Chairman | Feb 12 | Sale | 62.90 | 13,720 | 862,988 | 1,479,018 | Feb 13 06:30 PM | El-Hibri Fuad | Chairman | Feb 11 | Option Exercise | 25.62 | 6,280 | 160,894 | 1,485,298 | Feb 13 06:30 PM | El-Hibri Fuad | Chairman | Feb 11 | Sale | 62.90 | 6,280 | 395,012 | 1,479,018 | Feb 13 06:30 PM | El-Hibri Fuad | Executive Chairman | Feb 06 | Sale | 61.90 | 11,684 | 723,240 | 1,419,018 | Feb 07 06:31 PM | El-Hibri Fuad | Executive Chairman | Feb 05 | Sale | 60.66 | 48,316 | 2,930,849 | 1,430,702 | Feb 07 06:31 PM |
|
|
|
Index | - |
P/E | - |
EPS (ttm) | -10.15 |
Insider Own | 5.93% |
Shs Outstand | 3.23M |
Perf Week | -13.10% |
Market Cap | 131.67M |
Forward P/E | - |
EPS next Y | -5.29 |
Insider Trans | - |
Shs Float | 1.35M |
Perf Month | -20.40% |
Income | -32.90M |
PEG | - |
EPS next Q | -1.22 |
Inst Own | 75.20% |
Short Float | 12.28% |
Perf Quarter | 361.46% |
Sales | 11.00M |
P/S | 11.97 |
EPS this Y | 54.10% |
Inst Trans | 180.29% |
Short Ratio | 0.09 |
Perf Half Y | 314.67% |
Book/sh | 0.68 |
P/B | 47.81 |
EPS next Y | -16.00% |
ROA | -56.10% |
Target Price | - |
Perf Year | 234.12% |
Cash/sh | 6.15 |
P/C | 5.29 |
EPS next 5Y | - |
ROE | -199.50% |
52W Range | 2.94 - 60.00 |
Perf YTD | -11.30% |
Dividend | - |
P/FCF | - |
EPS past 5Y | 15.40% |
ROI | - |
52W High | -45.82% |
Beta | 7.49 |
Dividend % | - |
Quick Ratio | - |
Sales past 5Y | -6.60% |
Gross Margin | 44.10% |
52W Low | 1004.20% |
ATR | 2.33 |
Employees | 80 |
Current Ratio | 4.10 |
Sales Q/Q | - |
Oper. Margin | - |
RSI (14) | 36.67 |
Volatility | 6.40% 6.63% |
Optionable | No |
Debt/Eq | 11.45 |
EPS Q/Q | 37.40% |
Profit Margin | - |
Rel Volume | 0.04 |
Prev Close | 33.82 |
Shortable | Yes |
LT Debt/Eq | 11.45 |
Earnings | - |
Payout | - |
Avg Volume | 1.79M |
Price | 32.51 |
Recom | 1.70 |
SMA20 | -11.18% |
SMA50 | -15.96% |
SMA200 | 120.02% |
Volume | 73,145 |
Change | -3.87% |
|